PMID- 38260171 OWN - NLM STAT- MEDLINE DCOM- 20240124 LR - 20240228 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - Ferroptosis and metabolic syndrome and complications: association, mechanism, and translational applications. PG - 1248934 LID - 10.3389/fendo.2023.1248934 [doi] LID - 1248934 AB - Metabolic syndrome is a medical condition characterized by several metabolic disorders in the body. Long-term metabolic disorders raise the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Therefore, it is essential to actively explore the aetiology of metabolic syndrome (MetS) and its comorbidities to provide effective treatment options. Ferroptosis is a new form of cell death that is characterized by iron overload, lipid peroxide accumulation, and decreased glutathione peroxidase 4(GPX4) activity, and it involves the pathological processes of a variety of diseases. Lipid deposition caused by lipid diseases and iron overload is significant in metabolic syndrome, providing the theoretical conditions for developing ferroptosis. Recent studies have found that the major molecules of ferroptosis are linked to common metabolic syndrome consequences, such as T2DM and atherosclerosis. In this review, we first discussed the mechanics of ferroptosis, the regulatory function of inducers and inhibitors of ferroptosis, and the significance of iron loading in MetS. Next, we summarized the role of ferroptosis in the pathogenesis of MetS, such as obesity, type 2 diabetes, and atherosclerosis. Finally, we discussed relevant ferroptosis-targeted therapies and raised some crucial issues of concern to provide directions for future Mets-related treatments and research. CI - Copyright (c) 2024 Zhou, Lu, Mo, Yang, Chen, Yao, Xiong, Yue and Yang. FAU - Zhou, Dongmei AU - Zhou D AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Lu, Peipei AU - Lu P AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Mo, Xianglai AU - Mo X AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Yang, Bing AU - Yang B AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Chen, Ting AU - Chen T AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Yao, You AU - Yao Y AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Xiong, Tian AU - Xiong T AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. FAU - Yue, Lin AU - Yue L AD - School of Nursing, Hunan University of Medicine, Huaihua, China. FAU - Yang, Xi AU - Yang X AD - Department of Endocrinology, Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240108 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Lipid Peroxides) SB - IM MH - Humans MH - *Metabolic Syndrome/complications MH - *Diabetes Mellitus, Type 2/complications MH - *Ferroptosis MH - *Atherosclerosis MH - *Iron Overload/complications MH - Lipid Peroxides PMC - PMC10800994 OTO - NOTNLM OT - T2DM OT - atherosclerosis OT - ferroptosis OT - metabolic syndrome OT - obesity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/01/23 12:43 MHDA- 2024/01/24 06:43 PMCR- 2023/01/01 CRDT- 2024/01/23 10:35 PHST- 2023/06/27 00:00 [received] PHST- 2023/12/11 00:00 [accepted] PHST- 2024/01/24 06:43 [medline] PHST- 2024/01/23 12:43 [pubmed] PHST- 2024/01/23 10:35 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1248934 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2024 Jan 8;14:1248934. doi: 10.3389/fendo.2023.1248934. eCollection 2023.